Skip To Main Content
out-licensed to Asieris on Muck Rack

out-licensed to Asieris

As seen in: MFN.se
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with out-licensed to

Contact out-licensed to, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Photocure ASA: Results for the first quarter of 2026

|
By Erik Dahl, out-licensed to Asieris, biomarkers with Vesica
| MFN.se
Oslo, Norway, 7 May 2026 - Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 139.0 million in the first quarter of 2026 (Q1 2025: NOK 125.3 million), and an adjusted EBITDA of NOK 15.3 million (Q1 2025: NOK 9.7 million) for the company. In 2026, Photocure expects product revenue growth in the range of 7% to 11% on a constant currency basis and adjusted EBITDA margin expansion.
Open in Who Shared View Duplicates (198) Issue with article?
See all 1 articles